Vimpat under threat as UCB fights generic launches
This article was originally published in Scrip
UCB is suing Actavis, Novartis' Sandoz subsidiary and more than 13 other generics companies for patent infringement over their plans to market generic versions of the epilepsy drug Vimpat (lacosamide) in the US. In June, UCB filed a similar lawsuit in the US concerning Vimpat against Teva.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.